The third EURORDIS Multi-Stakeholder Symposium includes discussions with patient advocates, policy makers, payers, HTA bodies, clinicians, healthcare industry executives and investors on how to improve patients’ access to rare disease medicines.
Views expressed by participants will go towards producing a roadmap document, which will offer solutions and set out players' commitment to the goal of accelerating the development of, and guaranteeing timely and universal access to, rare disease therapies.
The roadmap will be disseminated to European and national institutions ahead of the May 2019 European parliamentary elections.
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.